Medical visa to India for residents of Algeria

Medical visa to India for residents of Algeria. Patients travelling from Algiers to India for treatment to connect with +91 96 1588 1588 for details & visa.

Share This Post

Medical visa to India for residents of Algeria can be given to patients who wishes to take medical treatment in India. Below mentioned is the complete details and procedure.

  • CancerFax helps in getting medical visa for medical treatment. Visa is granted up to one year with triple entries provided that registration is required after the patient reaches the country.
  • If one seeks medical treatment in top specialized/recognized  hospitals of India.
  • Up to  two attendants can accompany the patient who are closely related with him/her under separate attendant visas whose visa validity will be the same as the medical visa

Serious ailments like neurosurgery; ophthalmic disorders; heart – related problems; renal disorders; organ transplantation; congenital disorders; gene therapy; radio therapy; plastic surgery; joint replacement, etc. will be of primary consideration.
Document required for visa application

  • Indian visa application form.
  • Completed application form for India will be prepared within 5 business hours of order submission, and emailed to you to download, print and sign. IMPORTANT: Please note that ALL 3 PAGES of your application require your original signature! Also please note that each page of your application must be printed SINGLE-SIDED only. Applications printed/signed double-sided will be rejected. 
  • Original, signed Algeria passport with at least 6 months of remaining validity. 
  • Passport Photo: 1 Include a passport style photo, with a white background, taken within the last 6 months. You may also choose to upload a photo to your order for us to print. There is a surcharge associated with this service. 
  • Proof of status. Copy of Green Card (both sides) or other proof of legal status in the US (such as copy of I-20, US visa, H1B approval notice, etc. VisaHQ cannot assist US B1/B2 visa holders at this time.) 
  • Address in Algeria. If the traveler no longer maintains a residence in Algeria, they may provide their most recent residential address or the address of a relative. 
  • Driver’s license. Copy of driver’s license or state issued ID, or ORIGINAL major utility bill (Water, Gas, Electric, Sewage) for the most recent month, showing the applicant’s name and current address. The address must not contain a PO Box. Address MUST match home address in your applicant profile. 
  • Declaration Form. An original signed copy of the India Declaration Form. This form is available here.


Applicant must not wear glasses in their photographs.
Passport MUST contain at least two blank visa pages in order for the visa to be issued.


The link for visa application is given below


Medical fee[IN DINAR]

Embassy of India
Address : 17, domaine CHEKIKEN (Chemin de la Madeleine), Val d’Hydra, Algiers
Postal Address : BP.108, El Biar, 16030 Algiers, Algeria
Tel. No. : 00213 23 47 25 21/76
Fax No. : 00213 23 47 29 04
Website :
E-mail :;
Working Hours : 0900 – 1730 hrs (Sunday-Thursday, except closed holidays)
Ambassador : SH. SATBIR SINGH
Ambassador’s Office
  1. Attache/PS
: Smt. Anju Malik
  1. Attache/PS
: Sh. S.K.M. Hussaine
E-mail :


Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form